Vaxart (VXRT) AI Stock Analysis

• Market Cap: $82.18M
• Dividend Yield: N/A
• Average Volume (3M): 501.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.90
• Revenue Growth: 479.58%
• EPS Growth: 46.15%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 228,919,070
• 10 Day Avg. Volume: 543,618
• 30 Day Avg. Volume: 501,775
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 1.19
• Enterprise Value/Gross Profit: 1.19
• Enterprise Value/Ebitda: -2.17
• 1Y Price Target: $4.00
• Price Target Upside: 1011.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: $0.50 ▲(38.89% Upside)

Vaxart's overall score is primarily driven by its strong revenue growth but is significantly hampered by profitability issues and negative valuation metrics. Technical indicators suggest a bearish trend, and while the earnings call provided some positive developments, operational challenges and compliance issues weigh heavily on the stock's outlook.

Positive Factors

Revenue Growth

The significant increase in revenue indicates strong top-line expansion, driven by strategic contracts and partnerships, enhancing long-term growth prospects.

Innovative Vaccine Development

Successful preclinical trials for the avian influenza vaccine highlight Vaxart's potential for impactful vaccine innovations, supporting future partnerships and market expansion.

Norovirus Vaccine Progress

Positive Phase I results for the norovirus vaccine suggest promising advancements in Vaxart's pipeline, potentially leading to first-in-class or best-in-class offerings.

Negative Factors

Profitability Challenges

Persistent profitability issues, reflected in negative margins, indicate struggles in cost control and efficiency, potentially hindering long-term financial stability.

Nasdaq Listing Challenges

The suspension from NASDAQ due to listing compliance issues may limit investor access and liquidity, impacting the company's market perception and capital-raising ability.

Operational Uncertainties

The stop work order on a major trial introduces uncertainty in Vaxart's development timeline, potentially delaying product launches and affecting strategic goals.

Vaxart Business Overview & Revenue Model

Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

How the Company Makes Money

Vaxart generates revenue primarily through the development and commercialization of its vaccine candidates. This includes funding from government grants, research collaborations, and partnerships with other pharmaceutical companies. Key revenue streams include milestone payments from partners as vaccine candidates progress through clinical trials, as well as potential royalties on future sales of successful products. Additionally, Vaxart may engage in licensing agreements for its proprietary vaccine technology, which can provide upfront payments and ongoing royalties. The company's focus on innovative oral vaccines positions it to tap into funding opportunities for infectious disease prevention and control, especially in light of increasing global health challenges.

Vaxart Financial Statement Overview

Summary

Vaxart's financial performance is characterized by significant revenue growth and a strong gross profit margin, yet marred by high operating losses and negative cash flows. While the balance sheet shows some financial resilience due to cash reserves, the firm's profitability and cash flow generation remain major concerns. Continuous operating losses and reliance on external financing highlight the need for improved cost management and operational efficiency to achieve sustainable growth.

Income Statement

Vaxart's income statement shows a substantial increase in revenue over the years, with a notable jump to $47.4 million in the latest TTM period from $28.7 million the previous year. However, the company continues to operate at a loss, with a negative net profit margin of -122.6% and an EBIT margin of -120.6% in the TTM. The gross profit margin is strong at 97.7%, yet the persistent losses highlight challenges in controlling operating expenses and achieving profitability.

Balance Sheet

Vaxart's balance sheet indicates a moderate level of debt with a debt-to-equity ratio of 0.37 in the TTM. The equity ratio is 28.8%, showing reliance on equity financing. Despite a decrease in stockholders' equity over time, the company maintains a healthy level of cash and short-term investments, which provides some financial stability. However, the declining equity and high liabilities pose a risk.

Cash Flow

Cash flow analysis reveals negative operating cash flow of -$33.2 million and a negative free cash flow of -$33.7 million in the TTM, indicating the company is not generating sufficient cash from its operations. The free cash flow to net income ratio is negative, reflecting challenges in converting profits into cash. Despite these issues, financing activities have provided some liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.72M	28.70M	7.38M	107.00K	892.00K	4.05M
Gross Profit	80.72M	28.70M	2.88M	-80.95M	-47.86M	-15.82M
EBITDA	-44.20M	-54.87M	-72.13M	-103.12M	-66.45M	-28.26M
Net Income	-56.64M	-66.95M	-82.47M	-107.76M	-70.47M	-32.22M
Balance Sheet
Total Assets	164.09M	166.39M	91.83M	153.85M	221.17M	152.58M
Cash, Cash Equivalents and Short-Term Investments	26.27M	51.72M	39.71M	93.72M	166.49M	126.87M
Total Debt	16.11M	23.28M	26.51M	27.42M	24.53M	22.14M
Total Liabilities	131.21M	107.46M	34.02M	43.25M	33.64M	29.18M
Stockholders Equity	32.88M	58.92M	57.80M	110.60M	187.53M	123.40M
Cash Flow
Free Cash Flow	-37.17M	-45.32M	-72.32M	-104.38M	-64.99M	-24.97M
Operating Cash Flow	-37.09M	-44.76M	-70.45M	-94.78M	-59.83M	-23.75M
Investing Cash Flow	13.83M	-21.32M	43.95M	-20.41M	-49.10M	-1.22M
Financing Cash Flow	87.00K	56.56M	15.24M	17.46M	125.80M	138.31M

Vaxart Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VXRT, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.37, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.94 is Neutral, neither overbought nor oversold. The STOCH value of 43.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VXRT.

Vaxart Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MGNX	48 Neutral	$112.51M	―	-69.71%	―	303.47%	73.70%
ZNTL	46 Neutral	$114.70M	―	-49.55%	―	-33.76%	17.10%
SGMT	44 Neutral	$226.00M	―	-37.89%	―	-100.00%	-62.44%
VXRT	43 Neutral	$82.18M	―	-100.35%	―	479.58%	46.15%
OBIO	40 Underperform	$146.22M	―	-313.82%	―	41.61%	-17.39%
IMUX	37 Underperform	$96.51M	―	-208.93%	―	―	35.46%

Vaxart Corporate Events

Vaxart Adjourns Stockholder Meeting for Vote Solicitation

On September 5, 2025, Vaxart, Inc. adjourned its special meeting of stockholders to provide additional time for voting on proposals, including a reverse stock split. The meeting will reconvene on September 19, 2025, and during the adjournment, Vaxart will continue soliciting votes. This decision reflects recent changes in board composition and governance considerations, highlighting the company’s strategic focus on maintaining its Nasdaq listing and engaging with stockholders to maximize value.

The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Vaxart Announces Board Member Retirement

On September 2, 2025, Vaxart announced the retirement of Michael J. Finney, Ph.D., from its Board of Directors, effective September 30, 2025. Dr. Finney’s departure, due to personal reasons, led to a reduction in the board size from six to five members. His leadership and contributions were acknowledged as pivotal to Vaxart’s growth and mission. The board plans to meet to discuss future leadership and governance, aiming to continue advancing the company’s scientific progress.

The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Vaxart Secures Nasdaq Listing Continuation Approval

On August 27, 2025, Vaxart received a decision from the Nasdaq Hearings Panel allowing the company to continue its listing on Nasdaq, contingent upon meeting specific conditions including a reverse stock split by October 17, 2025. This decision follows a period of non-compliance with Nasdaq’s minimum bid price requirement, and the company is actively engaging with stockholders to secure their support for the necessary actions to maintain its listing, which is critical for its future success in the competitive vaccine industry.

The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Vaxart Discusses Reverse Stock Split Proposal

On August 20, 2025, Vaxart, Inc. held a virtual fireside chat with stockholders to discuss a proposed reverse stock split and its implications for the company’s NASDAQ listing. The management emphasized the importance of maintaining a NASDAQ listing for increased visibility, liquidity, and access to capital, which are crucial for advancing their vaccine development programs. The reverse stock split is seen as a strategic move to enhance the company’s market position and protect stockholder investments, with advisory firms ISS and Glass Lewis recommending support for the proposal.

The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.